Frank Borriello

Company: Alloplex Biotherapeutics Inc.

Job title: Chief Executive Officer

Seminars:

Epigenetic Reprogramming of Immune Cells: Suplexa Offers Orthogonal and Complementary Technology to Gamma Delta Cells 12:15 pm

SUPLEXA technology is applicable to lymphoid immune cells, conferring upon them a number of anti-tumor functions First-generation autologous SUPLEXA cells tested in a first-in-human study demonstrates single-agent activity in multiple solid tumors The technology is compatible with a variety of engineering approaches mediated by viral and mRNA vectorsRead more

day: Pre-Conference Day